Insertion of argos sequences into the B-loop of epidermal growth factor results in a low-affinity ligand with strong agonistic activity by Poll, M.L.M. van de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/26093
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Biochemistry 1997, 36, 7425-7431 7425
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a b s t r a c t :  Recently, it has been shown that the activation of the Drosophila EGF receptor (DER) by its 
natural ligand Spitz is inhibited by Argos [Schweitzer, R., et al. (1995) Nature 376 , 699 
and Spitz both have an EGF-like domain which in the case of Argos differs from that o f Spitz and other 
EGF receptor agonists in that it has an extended B-loop of 20 amino acids instead o f 10 amino acids 
which in addition contains an unusual cluster of charged residues. To investigate whether B-loop sequences 
are an important determinant for receptor activation and play a causal role in the antagonistic activity o f 
Argos, three human (h)EGF mutants were constructed in which amino acids derived from the Argos 
B-loop were introduced. In one mutant (E3A4E/B10), replacement of four amino acids in the B-loop of 
hEGF (123, E24, D27, and K28) by the corresponding Argos residues neither altered the binding affinity 
of the growth factor for the hEGF receptor nor did it change its ability to induce a mitogenic response. 
Insertion of 2 additional Argos residues (E3A4E/B12) or extension of the B-loop by 10 amino acids 
(E3A4E/B20) resulted, however, in a significant loss of binding affinity. In spite of this, both E3A4E/ 
B12 and E3A4E/B20 appeared to be strong agonists for the hEGF receptor with similar dose—response 
curves for mitogenic activity and MAPK activation as wild-type hEGF. These data show that several 
nonconservative substitutions in the hEGF B-loop are tolerated without affecting receptor binding or 
activation. Furthermore, they show that receptor binding and receptor signaling efficiency can be uncoupled 
which is a prerequisite for the development of receptor antagonists.
Epidermal growth factor (EGF) 1 belongs to a family of 
structurally related growth factors which all exert their action 
by binding to the epidermal growth factor receptor (Carpenter 
& Wahl, 1991). Many tumor cells express this receptor, and 
also secrete members of this family of EGF-like molecules, 
thus creating the possibility of an autocrine growth factor 
cycle. In particular, the role of transforming growth factor 
a  (TGF a) in the outgrowth of various tumors has been well 
established (Lee et al., 1995). Many studies have been 
performed on the structure—function relationship of EGF- 
like molecules, with the final aim of developing EGF- 
receptor antagonists, which can be used clinically to interfere 
with such autocrine processes (Carpenter & Wahl, 1991; 
Groenen et al., 1994; Prigent & Lemoine, 1992). 2D NMR 
studies have provided evidence that amino acids surrounding 
the second and sixth cysteine residues are in close contact
with each other, a nonlinear receptor
binding pocket (Hommel et al., 1992). Among these are 
Y13, L15, HI 6 , R41, E43, and L47 in hEGF. In addition, 
our previous data, using exchange mutants of hEGF and 
hTGFa, have shown that also R45 in hEGF belongs to the 
receptor binding domain (Van de Poll et al., 1995).
There is still discrepancy in the literature as to whether 
the B-loop of hEGF, the main /9-sheet structure, located
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review Groenen et al. (1994)], but EGF molecules with 
truncated forms of the B-loop have been claimed to be 
biologically active (Taggart et al., 1993). Domain- 
studies between EGF and TG Fa have also not given definite 
conclusions in this respect (Kramer et al., 
al., 1995).
In recent years, various studies have been performed on 
the characterization of EGF-like molecules in Drosophila.
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1992). If Argos indeed acts as an EGF receptor antagonist, 
this suggests that the B-loop might be an important deter­
minant for receptor activation.
In the present study, we have investigated the role of the 
hEGF B-loop in receptor binding and activation using three 
hEGF B-loop mutants in which the Argos B-loop charac­
teristics of aberrant length and charge distribution were 
introduced. The results show that the hEGF B-loop can be 
modulated to a high extent without loss of biological activity. 
Furthermore, it shows that it is possible to uncouple 
biological activity from binding affinity which is a prereq­
uisite for the development of receptor antagonists.
EXPERIMENTAL PROCEDURES
DNA Constructs. The synthetic gene for human EGF was 
obtained from British Biotechnology (Oxford, United King­
dom). Constructs encoding the hEGF B-loop mutants 
E3A4E/B20, E3A4E/B12, and E3A4E/B10 (Figure 1) were 
made by cleaving the gene coding for hEGF at the third 
cysteine codon with Nsil and at the fourth cysteine codon 
with Sphl. The gap was then filled in using double-stranded 
oligonucleotides. The genes were linked at the 5'-end to 
the sequence coding for the recognition sequence of the 
proteolytic enzyme factor Xa [Ile-Glu-Gly-Arg; see Nagai 
and Thogersen (1987)], and the FX/growth factor constructs 
were cloned into the expression vector pEZZ18 (Pharmacia, 
Uppsala, Sweden) 3' of the sequence coding for two synthetic 
protein A-derived IgG binding domains (so-called Z do­
mains) as described previously (Van de Poll et al., 1995; 
Kramer et al., 1994).
*
Expression and Purification o f Wild-Type and Mutant 
Growth Factors. Wild-type hEGF and the hEGF mutants 
were expressed and secreted as ZZ/FX/growth factor fusion 
proteins in the periplasmic space of Escherichia coli KS474, 
a degP protease-deficient mutant [a generous gift from Drs. 
K. L. Strauch and J. Beckwith, Harvard University; see 
Strauch et al. (1989) ]. The isolation of periplasmic proteins 
and the purification of recombinant growth factors were 
performed as described by Nilsson and Abrahmsen (1990) 
and Van de Poll et al. (1995). Briefly, this involved the 
binding of fusion proteins to IgG—Sepharose, removal of 
the protein A sequence by digestion with factor Xa followed 
by a second run on IgG—Sepharose, and a final purification 
step using HPLC on a Cm reverse phase column with a linear 
gradient of CH3CN in 0 .1 % trifluoroacetic acid.
Analysis o f Mutant Growth Factors by SDS— Polyacryl­
amide Gel Electrophoresis and Western Blotting. Fusion 
proteins were analyzed on a 12.5% SDS—polyacrylamide 
gel. The proteins were transferred to nitrocellulose (0.45 
/um), and the Western blots were probed with a rat anti-goat 
antibody linked to horseradish peroxidase to detect protein 
A sequences. Enzyme activity was detected by incubation
with tetramethylbenzidine/sodium dioctylsulfosuccinate/H202 
in phosphate/citrate buffer (pH 5).
Purified growth factors were analyzed on a 16.5% T/6 % 
C tricine SDS—polyacrylamide gel in the presence of 2 % 
/3-mercapto'ethanol as a reducing agent (Schagger & Von 
Jagow, 1987). The proteins were transferred to nitrocellulose 
(0.1 (A.m), and the Western blots were incubated at room 
temperature with a polyclonal antibody (Ab-3) raised against 
recombinant hEGF (Oncogene Science Inc., Cambridge, 
MA). Previous studies have shown that this antibody
recognizes a hEGF/hTGFa chimera in which the hEGF 
B-loop had been replaced by hTGFa (Van de Poll, unpub­
lished results). Probed proteins were detected by a goat anti­
rabbit antibody linked to horseradish peroxidase and visu­
alized by enhanced chemiluminescence (ECL, Boehringer, 
Mannheim).
Quantification o f Mutant (Fusion) Proteins. The amount 
of ZZ/FX/growth factor fusion protein present in the un­
purified periplasm was estimated by measuring the total 
amount of IgG binding activity. This was done in a 
competitive enzyme-linked immunosorbent assay using 
protein A as a standard and biotin-labeled protein A as a 
competitor [both obtained from Sigma Chemical Co., St. 
Louis, MO; see Van Zoelen et al. (1993)]. The amount of 
growth factor obtained after the final purification by RP- 
HPLC was calculated from the peak area (absorption at 229 
nrn) using natural murine (m)EGF (Bioproducts for Science 
Inc., Indianapolis, IN) analyzed under the same conditions 
as a standard.
[I25I]-mEGF Binding Competition Assay. The ability of
the fusion proteins and the purified growth factors to bind 
to the hEGF receptor was measured in an [125I]-mEGF 
binding competition assay on confluent layers of NIH-3T3 
fibroblasts transfected with the hEGF receptor (HER-14 cells, 
4.0 x  103 receptors/cell) as described previously (Van de 
Poll et al., 1995). Shortly, serial dilutions of lyophilized 
periplasm or purified growth factors were made in serum- 
containing Dulbecco’s modified Eagle’s medium (DMEM), 
buffered at pH 7.7 with 15 mM HEPES [4-(2-hydroxyeth- 
yl)piperazine-1-ethanesulfonic acid], and 100piL was added 
to the cells together with 0.1 ng/well [125I]~mEGF. After 
incubation for 2  h at room temperature, cells were washed 
twice with ice-cold phosphate-buffered saline (PBS)/ 0 .1% 
bovine serum albumin (BSA) and once with ice-cold PBS. 
The cells were incubated subsequently in 1% Triton X-100 
for 1 h at room temperature prior to y-counting. Experiments
using natural mEGF as awere performed in 
standard and repeated twice.
Mitogenic Assay. HER-14 cells were seeded in gelatinized 
24-well dishes at a density of 6.0 x 104 cells/well in 1 mL 
of DMEM containing 10% newborn calf serum (NCS).
24 h of incubation, the medium was replaced by 0.9 mL of 
DMEM/Ham’s F I2  medium (1:1) supplemented with 30 nM 
NaoSeO.i, 10 /.£ g/m L human transferrin, and 0.5% BSA. After 
an additional 48 h of incubation, serial dilutions of lyophi­
lized periplasm or purified growth factor were added in 0.1 
mL of DMEM containing 50 mM BES [7V,/V-bis(2-hydroxy- 
ethyl)-2-aminoethanesulfonic acid, pH 6 .8]. Eight hours 
later, 0.5 /.iCi of [3H]thymidine was added in 0.1 mL of 
Ham’s FI 2 medium. Incorporation of the tracer into cellular 
DNA was determined 24 h after growth factor addition. For 
this, cells were washed twice with PBS and subsequently 
fixed with methanol at room temperature. After 15 min, the 
methanol was aspirated, and the cells were lysed in 1 mL of 
0.2 N NaOH for 30 min at 37 °C as described (Van Zoelen 
et al., 1985). Radioactivity was determined by liquid 
scintillation counting. Experiments were performed in 
duplicate and repeated twice.
Mitogen-Activated Protein Kinase (MAPK) Assay. HER- 
14 cells were grown to confluence in 6 -well dishes (9.8 cm2) 
and subsequently incubated for 48 h in 950 /uL of DMEM 
supplemented with 0.1% BSA. Serial dilutions of recom­
binant growth factors were added in 50 juL of DMEM
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F igu re 1: Primary sequence of the B-loop of wild-type and mutant 
proteins. In the hEGF mutant E3A4E/B20, the B-loop of hEGF 
was extended by 10 amino acids derived from the Argos B-loop. 
In E3A4E/B12  and E3A4E/B10, four amino acids in the hEGF 
B-loop (123, E24, D27, and K28) were replaced by respectively 
six and four residues from the Argos B-loop. Individual amino acids 
in the B-loop are indicated: boxes, hEGF-derived amino acids; 
boxes with arrow, Argos-derived amino 
conserved third and fourth cysteine residues.
buffered at pH 6 .8  with 50 mM BES and incubated for 10 
min at 37 °C. Then the medium was aspired, and the cells 
were washed once with ice-cold PBS and rapidly lysed in
300 juL of sample buffer (10% glycerol, 60 mM Tris*HCl, 
pH 6 .8 , 2 % SDS, 0.3 M /3-mercaptoethanol, and bromo- 
phenol blue). The lysate was sheared and boiled for 10 min. 
Aliquots of 50 ¡uL were analzed by gel electrophoresis on a 
12.5% SDS—polyacrylamide gel. Proteins were transferred 
to nitrocellulose, and the blots were probed with a polyclonal 
antibody directed against MAPK (Burgering et al., 1993). 
Probed proteins were detected by a goat anti-rabbit antibody 
linked to horseradish peroxidase and visualized by ECL. The 
bands representing the phosphorylated and the unphospho- 
rylated MAPK were scanned, and the amount of phospho­
rylated MAPK was expressed as a percentage of total MAPK 
in HER-14 cells. Experiments were repeated twice.
RESULTS
hEGF B-Loop Mutants. The EGF-like motif of Argos 
contains 20  amino acids between the third and fourth cysteine 
residue whereas this so-called B-loop sequence in hEGF 
consists of only 10 amino acids. To evaluate the effect of 
a B-loop extension on receptor binding and activation, 10
B-loop were insertedresidues derived from the 
between A25 and L26 in hEGF. The resulting hEGF B-loop 
mutant thus contained a B-loop of 20 amino acids similar to 
Argos and was designated E3A4E/B20 (Figure 1).
Another characteristic of the Argos B-loop is the presence 
of a cluster of basic amino acids opposite to acidic amino 
acids. Therefore, two mutants were constructed in which 
four amino acids of the hEGF B-loop (123, E24, D27, K28) 
were replaced by four (KRDE) or six (RKRDEV) residues 
derived from the Argos B-loop. These mutants thus con­
tained a B-loop of respectively 10 and 12 amino acids and 
were designated E3A4E/B10 and E3A4E/B12 (Figure 1).
Expression and Purification o f Mutant Growth Factors. 
Wild-type and mutant growth factors were expressed and 
excreted into the periplasmic space of E. coli KS474 as ZZ/ 
FX/fusion proteins. Analysis of 10 fih  of unpurified 
periplasm by SDS—polyacrylamide gel electrophoresis and 
Western blotting showed a major band migrating at ~20 kDa 
in the wild-type hEGF and the E3A4E/B10 and E3A4E/B12
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F ig u re  2: RP-I-IPLC chromatogram of E3A4E/B20. Elution was 
earned out with a linear gradient of CH3CN in 0.1% trifluoroacetate 
at a flow rate of I mL/min. Biological activity in the column 
fractions (1 mL) was determined in a binding competition assay 
with [125I]-mEGF. Most of the activity was present in two major 
protein products (peaks a and b) eluting at ~35% acetonitrile. Peaks 
a and b were pooled, and the combined product was designated 
E3A4E/B20.
samples, corresponding to monomeric ZZ/FX fusion proteins 
(the two IgG binding domains together have a molecular 
mass of 14 kDa). In the E3A4E/B20 sample a band 
migrating at ~ 2 2  kDa was visible, corresponding to mon­
omeric ZZ/FX/E3A4E/B20 (data not shown). In all samples, 
minor bands of higher molecular weight were also present 
representing multimeric forms of the fusion proteins.
Small-scale preparations (100 mL cultures) were made of 
the E3A4E/B10 and E3A4E/B12 mutants, and these mutants 
were tested for activity as fusion proteins without further 
purification. The expression level of fusion protein in these 
cultures was found to be close to 200 pmol/mL IgG binding 
activity for the mutant growth factors and 370 pmol/mL for 
wild-type hEGF.
A large-scale preparation (5 L culture) was made of the 
hEGF B-loop mutant E3A4E/B20, and the growth factor was 
purified to homogeneity. Analysis of the biological activity 
present in the RP-HPLC fractions in a binding competition 
assay with (l25I]-mEGF showed that most of the activity was 
present in two major products (peaks a and b) eluting at 
~35% acetonitrile (Figure 2). Some activity was also found 
to coelute with several minor products eluting in front of 
E3A4E/B20. The identity of these proteins could not be
to their low For technical
reasons, the two major products were pooled, and the pooled 
fraction was subsequently analyzed by SDS—polyacrylamide 
gel electrophoresis.
Identification o f E3A4E/B20. Analysis of purified recom­
binant growth factors on SDS—polyacrylamide gel under 
reducing conditions showed that both wild-type hEGF and 
E3A4E/B20 migrated as a single band at the expected 
molecular mass of ~ 6  and 7.5 kDa, respectively (Figure3).
The molecular weight of E3A4E/B20 was confirmed by 
mass spectrometry (carried out in collaboration with Dr. M. 
O’Connor-McCourt and Dr. Y, Konishi,
Research Institute, Montreal). Analysis of the combined 
mutant product identified a major product (67%) with an 
average compound mass of 7518 Da corresponding to the 
predicted MW of E3A4E/B20, and a minor product (33%) 
with an average compound mass of 7535 Da. The exact 
nature of the latter compound was not established, but the
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F igure 3: Identification of E3A4E/B20 by SDS—polyacrylamide 
gel electrophoresis and Western blotting. RP-HPLC-purified E3A4E/ 
B20 was analyzed on a 16.5% T/6% C tricine SDS-polyacrylamide 
gel under reducing conditions. The migration of E3A4E/B20 was 
compared with recombinant wild-type hEGF expressed in the same 
system and purified under the same conditions. Proteins were 
transferred to nitrocellulose, and the Western blots were probed 
with a polyclonal antibody raised against recombinant wild-type 
hEGF. Detection was by enhanced chemiluminescence (ECL): 
hEGF, lane 1; E3A4E/B20, lane 2.
higher molecular weight could be the result of a chemical 
modification, e.g., oxidation of M21, which is known to 
occur during storage and does not affect the biological 
activity of wild-type EGF (Carpenter & Wahl, 1991).
It is concluded that the main component of the combined 
mutant product is a single-chain protein with the expected 
characteristics of E3A4E/B20.
Binding Affinity of Mutant Growth Factors for the hEGF 
Receptor. The binding activity of the mutant growth factors 
was measured in a [123I]-mEGF binding competition assay 
on confluent layers of HER-14 cells. RP-HPLC-purified 
E3A4E/B20 was compared in assay pur
recombinant wild-type hEGF, whereas the activity of the 
E3A4E/B10 and E3A4E/B12 fusion proteins was compared 
with wild-type hEGF fusion protein expressed in a parallel 
culture. Exchange of the hEGF B-loop residues 123, E24, 
D27, and K28 for four Argos-derived amino acids, KRDE, 
as in E3A4E/B10 did not significantly reduce the binding 
affinity of hEGF for its receptor (Figure 4A). The amount 
of E3A4E/B10 fusion protein required for 50% displacement 
of [12sI]-mEGF (IC5{)) was 20 ±  1 pmoI/mL, and the IQo 
calculated for hEGF fusion protein was 22  ±  2 pmoI/mL. 
However, extension of the B-loop by only two amino acids 
in the E3A4E/B12 mutant caused already a 7-fold reduction 
in EGF receptor binding affinity (Figure 4A; IC50 of 149 ±  
0 pmoI/mL). The affinity of E3A4E/B20, which has a 
B-loop of 20 amino acids as in Argos, was likewise reduced, 
being only ~5% of wild-type growth factor (Figure 4B; IC50 
of 53 ±  10 pmol/mL compared to 3.3 ±  0.3 pmol/mL for 
wild-type hEGF).
Mitogenicity of Mutant Growth Factors. The E3 A4E/B10 
and E3A4E/B12 fusion proteins (Figure 5A) and HPLC- 
purified E3A4E/B20 (Figure 5B) were tested for their ability 
to stimulate the incorporation of [3H] thymidine into the 
cellular DNA of quiescent HER-14 cells. The mitogenic 
activity of the mutant fusion proteins was compared with 
hEGF fusion protein (ZZ/FX/hEGF) as well as with purified 
recombinant hEGF. Furthermore, it was verified that no 
dose-dependent increase in [3H]thymidine incorporation
mEGF or ZZ/FX/fusion protein (pmol/ml)
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F igu re  4: Inhibition of binding of [125I|-mEGF to HER-14 cells. 
The binding activity of unpurified ZZ/FX/fusion protein of the 
E3A4E/B12 and E3A4E/B10 mutants was measured in a [l25IJ- 
mEGF binding competition assay on HER-14 cells. The affinity of 
the mutant fusion proteins was compared with wild-type hEGF 
fusion protein (ZZ/FX/hEGF) expressed in a parallel culture (A):
(▲) ZZ/FX/hEGF; (A) ZZ/FX/E3A4E/B10; (■) ZZ/FX/E3A4E/ 
B12; (O) ZZj— (control periplasm obtained from KS474 trans­
formed with pEZZlB vector without growth factor insert). The 
ability of RP-HPLC-purified E3A4E/B20 to compete with [12SIj- 
mEGF for binding to HER-14 cells was compared with that of wild- 
type recombinant hEGF expressed in the same system and purified 
under the same conditions (B): (+) hEGF; (O) E3A4E/B20. The 
concentration of fusion protein and purified growth factor was 
determined as described under Experimental Procedures. Repre­
sentative curves of three experiments are shown.
occurred after incubation with control periplasm and that 
control periplasm did not alter the mitogenic res
HER-14 cells to purified recombinant hEGF.
Figure 5A,B shows that all three mutants are agonists of 
the human EGF receptor with similar dose—response curves 
for the induction of mitogenic activity as wild-type hEGF. 
The protein concentration required to give 50% stimulation 
of [3H]thymidine incorporation (EC50) was estimated to be 
0.23 ±0.15 and 0.25 ±  0.08 for the E3A4E/B10 and E3A4E/ 
B 12 fusion protein, respectively, and the EC50 of purified
E3A4E/B20 was calculated to be 0.08 ±  0 .0 2  compared to 
0.15 ±  0.02 for purified recombinant hEGF. Thus, in spite 
of the fact that E3A4E/B20 and E3A4E/B12 display a
to bind the human EGF receptor,
they are as as wild-type hEGF in •ating a
mitogenic response in quiescent HER-14 cells.
m-Activated Protein Kinase (MAPK) Activation. To 
investigate whether the observed divergence between receptor
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F igu re 5: Mitogenic response of HER-14 cells. Mitogenic activity 
was assessed by measuring [3H]thymidine incorporation into the 
cellular DNA of serum-starved HER-14 cells 24 h after growth 
factor addition. The mitogenic response induced by the Z27FX/ 
fusion proteins of the E3A4E/B12 and E3A4E/B10 mutants was 
compared with the response induced by wild-type hEGF fusion 
protein and purified recombinant hEGF (A). The mitogenic activity 
is expressed relative to the radioactivity incorporated in the presence 
of 10% NCS (191 592 ±  8079 cpm): (+  -  + ) hEGF; (A) ZZ/
FX/hEGF; (A )  ZZ/FX/E3A4E/B10; (■) ZZ/FX/E3A4E/B12; (O) 
control periplasm obtained from KS474 transformed with pEZZIS 
vector without growth factor insert; (+  —  + ) control periplasm 
to which purified recombinant hEGF is added. The mitogenic 
response generated by RP-HPLC-purified E3A4E/B20 was com­
pared with wild-type recombinant hEGF expressed in the same 
system and purified under the same conditions (B). The mitogenic 
activity is expressed relative to the radioactivity incorporated in 
the presence of 10% NCS (192 543 ±  9805 cpm): (+) hEGF; (O) 
E3A4E/B20. Representative curves of three experiments are 
presented.
binding affinity and mitogenicity is due to an uncoupling of 
binding ability and signaling efficiency, E3A4E/B20 was 
tested for its ability to induce MAPK phosphorylation in 
HER-14 cells. Figure 6 shows that, in spite of its very low 
binding ability, E3A4E/B20 is also a relatively potent 
activator of MAPK, being only 2—3 times less active than 
wild-type hEGF. This indicates that also MAPK activation 
by E3A4E/B20 is not a reflection of the equilibrium binding 
constant of the mutant growth factor.
F ig u r e  6: Induction of MAPK phosphorylation by E3A4E/B20. 
MAPK activation was measured after 10 min of incubation of HER- 
14 cells with serial dilutions of wild-type hEGF or E3A4E/B20. 
The proteins were analyzed on a 12.5% SDS—polyacrylamide gel 
and transferred to nitrocellulose. The blots were probed with a 
polyclonal antibody directed against MAPK, and detection was by 
enhanced chemiluminescence: (+) hEGF; (O) E3A4E/B20.
DISCUSSION
antagonist
ized by the presence of an unusual B-loop sequence 
consisting of 2 0  amino acids as opposed to 10 residues in 
known EGF receptor agonists. In addition, this sequence in 
Argos contains a cluster of positively charged amino acids 
opposite to negatively charged residues (Freeman et al., 
1992). To investigate the effect of an enlargement of the 
B-loop and/or the introduction of charged side chains in 
hEGF on receptor binding and activation, three hEGF 
mutants were constructed containing aberrant B-loop se­
quences derived from the DER antagonist Argos.
The simultaneous mutation of three amino acids, I23K, 
E24R, and K28E, as in the E3A4E/B10 mutant neither 
affected the affinity of the growth factor for the hEGF 
receptor nor lowered its ability to stimulate the proliferation 
of quiescent HER-14 cells. Additional pairwise insertion 
of a lysine and a valine residue (E3A4E/B12) or an extension 
of the hEGF B-loop by 10 amino acids derived from Argos 
(E3A4E/B20) resulted in a significant loss of binding affinity, 
however, without a concomitant 
potency. All three mutants appeared to be as mitogenic as 
wild-type hEGF.
Ever since the first report by Komoriya et al. (1984) that 
a synthetic linear peptide corresponding to the B-loop 
sequence of murine EGF is biologically active when added 
at high concentrations, the B-loop /i-sheet has been the 
subject of extensive research. Point mutation studies have 
frequently indicated 123 as an important determinant for high- 
affinity receptor binding [reviewed in Groenen et al. (1994)]. 
Only the nonpolar residues valine and leucine can replace 
123 without significant loss of binding affinity, and a lysine 
residue at this position, as in E3A4E/B10, was thus expected 
to lower the affinity. Our observation that E3A4E/B10 has 
a similar high affinity as wild-type hEGF for the hEGF 
receptor suggests that specific pairwise mutations in the 
B-loop may have less impact on receptor binding than single-
m
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point mutations and that the effect of the I23K mutation may 
be more or less compensated for by the K28E mutation.
Another prerequisite for high-affinity binding seems to be 
the correct length of the B-loop. Pairwise insertion of only 
2 amino acids in the E3A4E/B12 mutant already resulted in 
a 7 -fold reduction in binding affinity while further extension 
of the B-loop to 20 amino acids in E3A4E/B20 caused an 
additional 2-fold reduction. Whether the reduced affinity is 
due to the introduction of specific amino acids or whether 
any enlargement of the B-loop sequence, even if it is only 
by two amino acids, is not tolerated is at present not known, 
blit the fact that most of the mammalian EGF receptor 
agonists, such as EGF, TGFa, amphiregulin, heparin binding 
EGF, betacellulin, and epiregulin, have B-loop sequences 
consisting of only 10 amino acids (Groenen et al., 1994) is 
in favor of the latter explanation. Furthermore, the poxvirus 
family members Shope fibroma growth factor and myxoma 
growth factor with 13 residues located between the third and 
fourth cysteine residues have a strongly reduced affinity 
compared to hEGF (Lin et al., 1988, 1991). In addition, we 
have found that a shortening of the B-loop by pairwise 
deletion of four or six amino acids also causes a strong 
reduction in binding affinity and biological activity (M. L. 
M. van de Poll, unpublished results).
Although E3A4E/B12 and E3A4E/B20 displayed strongly 
reduced binding affinity for the hEGF receptor, they were 
as potent as wild-type hEGF in generating a mitogenic 
response in cells expressing the hEGF receptor. Uncoupling 
of binding affinity and signaling efficiency has so far been 
described for only one EGF mutant, mEGF L47V, and it 
was suggested that the relative high mitogenic potency of 
this mutant was associated with a resistance to receptor- 
mediated degradation (Walker et al., 1990). E3A4E/B20, 
however, is not likely to be more resistant to degradation 
than wild-type hEGF since both proteins share the same 
C-terminal region. For most of the other EGF analogues 
studied to date, receptor binding affinity and biological 
activity seem to be strongly correlated.
It has been well established that cells can contain both 
high- and low-affinity EGF receptors, and it has been put 
forward that cellular responses are mainly mediated by the 
high-affinity receptor sites (Defize et al., 1989; Walker et
a l , Since high-affinity receptors have a
relatively low abundance, it is theoretically possible that 
E3A4E/B20 has similar affinity as hEGF for the high-affinity 
receptors, resulting in similar mitogenic activity, and only 
differs from hEGF by its strongly reduced affinity for the 
low-affinity receptors. It has been shown that low-affinity 
receptors can be extracted from the cells by Triton X-100, 
since they are not linked to the cytoskeleton (Van Bergen 
en Henegouwen et al., 1988; Berkers et al., 1990). Using 
this approach, we observed that the remaining 5% high-
affinity receptors still had a 20-fold lower affinity for E3A4E/ 
B20 than for hEGF, indicating that the difference between
and mitogenic potential of E3A4E/B20 
cannot be explained in this way.
In recent years, it has also become clear that the EGF 
receptor is a member of a multigene family, and that EGF- 
like growth factors can induce receptor heterodimers of 
which particularly those with erbB2 appear to generate the 
most potent mitogenic signals (Qian et al., 1994; Graus-Porta 
et al., 1995; Karunagaran et a l, 1996; Pinkas-Kramarski et 
al., 1996). The HER-14 cell line used in our studies
expresses a low level of endogeneous erbB2. It could be 
argued therefore that E3A4E/B20 only differs from hEGF 
in its ability to bind EGF receptor homodimers but can induce 
EGF receptor/erbB2 heterodimers with similar potency as 
hEGF resulting in a similar mitogenic response. Preliminary 
results using IL-3-dependent myeloid cells transfected with 
only erbBl, however, show that heterodimerization is not 
required for the high mitogenic activity of E3A4E/B20 (A. 
E. G. Lenferink and Y. Yarden, unpublished observation). 
Furthermore, we found that the relatively high mitogenic
4
potency of E3A4E/B20 was accompanied by a relatively high
M A PK M APK
tion is achieved already 5—10 min after growth factor 
addition, the rate of phosphorylation of this second messenger 
most likely reflects the time required for the ligand to interact 
with the receptor and is not related to the equilibrium binding 
constant. Recent BIAcore experiments with several EGF/ 
TGFa chimeras suggest that a high ability to activate MAPK 
indeed correlates with a high association rate constant (A. 
E. G. Lenferink and M. O’Connor-McCourt, unpublished 
results). The fact that E3A4E/B20 is as potent as wild-type 
hEGF in the MAPK assay might indicate that its association 
rate constant is similar to hEGF and that the low affinity 
might be due to a higher /c0it- We are currently investigating 
this. If the association rate rather than the equilibrium 
binding constant appears to be an important determinant for 
mitogenic activity, this would pose a new concept on how 
receptor activation occurs and how a biological response is 
generated.
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Corrections
Estrone Sulfatase: Probing Structural Requirements for 
Substrate and Inhibitor Recognition, by Cynthia Anderson, 
Jennifer Freeman, Linda H. Lucas, Michael Farley, Habib Dal- 
houmi, and Theodore S. Widlanski*, Volume 36, Number 
9, March 4, 1997, pages 2586—2594.
Page 2594. The paragraph below did not appear in the 
published paper.
SUPPORTING INFORMATION AVAILABLE
Lineweaver—Burk plots, secondary replots, and 31P NMR- 
based titration curves (34 pages). Ordering information is 
given on any current masthead page.
BI9750089
Insertion of Argos Sequences into the B-Loop of Epidermal 
Growth Factor Results in a Low-Affinity Ligand with Strong 
Agonistic Activity, by Monique L. M. van de Poll,* 
Marianne J. H. van Vugt, Anne E. G. Lenferink, and 
Everardus J. J. van Zoelen, Volume 36, Number 24, June 
17, 1997, pages 7425-7431.
Page 7429. In Figure 6, the x-axis should read growth 
factor (fmol/mL).
BI975018+
The D-Helix in Myoglobin and in the Subunit of 
Hemoglobin Is Required for the Retention of Heme, by 
Timothy L. Whitaker, Michael B. Berry, Emai L. Ho, 
Mark S. Hargrove, George N. Phillips, Jr., Noboru H. Ko- 
miyama, Kiyoshi Nagai, and John S. Olson*, Volume 34, 
Number 26, July 4, 1995, pages 8221—8226.
Page 8221 and throughout the article. The myoglobin 
mutants contain deletions or substitutions in residues 52— 
56 and not residues 51 —55. Thus, D-helix mutants of sperm 
whale myoglobin have (1) deletion of Glu52-AIa-Glu-Met- 
Lys56, Mb(—D52-56); (2) replacement of these residues with 
Ala52-Ala-Ala-Ala-Ala56, Mb(Ala52-56); or (3) replacement 
of these residues with Ala52-Ala-Ala-Met55-Ala56, 
Mb(Ala52-54Met55Ala56). These mutations have been recon­
firmed by both high-resolution crystallography and sequenc­
ing of the original genes.
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